ATE483978T1 - Anti-epha2 antikörper als krebsdiagnostikum - Google Patents

Anti-epha2 antikörper als krebsdiagnostikum

Info

Publication number
ATE483978T1
ATE483978T1 AT00955686T AT00955686T ATE483978T1 AT E483978 T1 ATE483978 T1 AT E483978T1 AT 00955686 T AT00955686 T AT 00955686T AT 00955686 T AT00955686 T AT 00955686T AT E483978 T1 ATE483978 T1 AT E483978T1
Authority
AT
Austria
Prior art keywords
epha2
cancer diagnostic
epha2 antibodies
kits
overexpressed
Prior art date
Application number
AT00955686T
Other languages
German (de)
English (en)
Inventor
Michael Kinch
Nicole Zantek
Katherine Kilpatrick
Original Assignee
Purdue Research Foundation
Glaxo Group Ltd
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Glaxo Group Ltd, Univ North Carolina filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of ATE483978T1 publication Critical patent/ATE483978T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00955686T 1999-08-17 2000-08-17 Anti-epha2 antikörper als krebsdiagnostikum ATE483978T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14925999P 1999-08-17 1999-08-17
PCT/US2000/022669 WO2001012840A2 (en) 1999-08-17 2000-08-17 Anti-epha2 antibodies as a cancer diagnostic

Publications (1)

Publication Number Publication Date
ATE483978T1 true ATE483978T1 (de) 2010-10-15

Family

ID=22529464

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00955686T ATE483978T1 (de) 1999-08-17 2000-08-17 Anti-epha2 antikörper als krebsdiagnostikum

Country Status (8)

Country Link
EP (2) EP2312316A1 (enExample)
JP (3) JP4948728B2 (enExample)
AT (1) ATE483978T1 (enExample)
AU (1) AU785445C (enExample)
CA (1) CA2382655A1 (enExample)
DE (1) DE60045075D1 (enExample)
ES (1) ES2357296T3 (enExample)
WO (1) WO2001012840A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
AU2001256970C1 (en) 2000-03-31 2008-07-03 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
WO2003004529A2 (en) * 2001-07-02 2003-01-16 Licentia Ltd. Ephrin-tie receptor materials and methods
CA2461877A1 (en) * 2001-09-28 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
EP1453530A2 (en) * 2001-11-09 2004-09-08 Neuronova AB Method of proliferation in neurogenic regions
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
WO2003094859A2 (en) * 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) * 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
CA2486615A1 (en) 2002-05-23 2003-12-04 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target
JP4838720B2 (ja) 2003-05-13 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 転移および転移がもたらす骨格関連現象を調節する方法
CA2542631A1 (en) * 2003-10-15 2005-04-28 Medimmune, Inc. Listeria-based epha2 vaccines
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
KR101363252B1 (ko) * 2005-02-04 2014-02-13 레이븐 바이오테크놀로지스, 인코퍼레이티드 Ｅｐｈａ2에 결합하는 항체 및 그것의 사용방법
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
WO2009028639A1 (ja) 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
JP6069806B2 (ja) * 2013-02-13 2017-02-01 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6399013B2 (ja) * 2016-02-18 2018-10-03 トヨタ自動車株式会社 化学蓄熱器の制御装置
WO2018034332A1 (ja) * 2016-08-19 2018-02-22 国立大学法人東京大学 ＥｐｈＡ２ Ｎ末端フラグメント抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514554A (en) 1991-08-22 1996-05-07 Becton Dickinson And Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5876949A (en) 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same

Also Published As

Publication number Publication date
EP2312316A1 (en) 2011-04-20
EP1210603A2 (en) 2002-06-05
JP2007291140A (ja) 2007-11-08
AU785445C (en) 2008-01-31
ES2357296T3 (es) 2011-04-25
WO2001012840B1 (en) 2001-09-27
AU785445B2 (en) 2007-06-14
AU6784300A (en) 2001-03-13
JP2003507023A (ja) 2003-02-25
JP4948728B2 (ja) 2012-06-06
DE60045075D1 (de) 2010-11-18
WO2001012840A3 (en) 2001-05-03
CA2382655A1 (en) 2001-02-22
JP2012103264A (ja) 2012-05-31
EP1210603B1 (en) 2010-10-06
WO2001012840A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
ATE483978T1 (de) Anti-epha2 antikörper als krebsdiagnostikum
EP1585966B8 (en) Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4
RU2005131842A (ru) Моноклональное антитело и продуцирующая его гибридома
RU2001102598A (ru) Способ ранней диагностики карцином
CA2384579A1 (en) Early cancer tumor marker
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
WO2005113000A3 (en) Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
WO2001075177A3 (en) Tumor markers in ovarian cancer
Ahmad et al. Antigens, antibodies, and membranous nephropathy: a decade of progress
WO2007121465A3 (en) Detection of proteins from circulating neoplastic cells
NZ288235A (en) Monoclonal antibody directed against the receptor tyrosine kinase flt4 and use in diagnosis and therapy
CA2908515A1 (en) Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
US20130216523A1 (en) Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
CN111273012A (zh) 一种血清自身抗体联合检测的方法
EP0163303A3 (en) Human monoclonal antibodies to cell surface and intracellular antigens
EP1214447B8 (de) Nachweis des pyruvatkinase-isoenzyms im stuhl
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
ATE394676T1 (de) Verbindungen und verfahren zur diagnose von prostatakrebs
WO1998022825A3 (en) A whole blood/mitogen assay for the early detection of a subject with cancer and kit
DK1907842T3 (da) Identifikation af ikke-småcellede lungecarcinom-tumorer (NSCLC) udtrykkende PDGFR-alfa
WO2005114203A3 (en) Dominant b cell epitopes and methods of making and using thereof
WO2003001884A3 (en) Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer
Fang et al. Quantum dots for cancer diagnosis
WO2003099104A3 (en) Elisa assay of serum soluble cd22 to assess tumor burden/relapse in subjects with leukemia and lymphoma
RU2003111512A (ru) Способ прогнозирования рецидивов и метастазов рака легкого

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties